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Background: Selective serotonin reuptake inhibitors are primarily used in the pharmacological 
treatment of patients experiencing a major depressive disorder. However, one of the common 
unwanted effects is excessive sweating or hyperhidrosis. Oxybutynin is an anticholinergic 
medication which reduces sweating. The aim of this double-blind study was to examine the effect 
of administration of oxybutynin on subjective sweating in patients treated with sertraline.
Methods: A total of 140 patients experiencing a major depressive disorder (mean age 
37.69 ± 10.44 years, 86 females [61.4%]) treated with sertraline (mean dose 83 mg/day) 
were consecutively enrolled in the study, and all reported excessive sweating as a side effect. 
Thereafter, the patients were randomly assigned to either an oxybutynin 5 mg/day group or to a 
placebo group. At the beginning and end of the 2-week trial, the patients completed questionnaires 
related to sweating and medication-related side effects.
Results: Over time, subjective sweating reduced significantly in the treatment group as compared 
with the control group. Oxybutynin-induced side effects were uncommon. Relative to male 
patients, female patients reported less subjective sweating.
Conclusion: Administration of oxybutynin successfully reduced excessive sweating in patients 
experiencing a major depressive disorder and treated with sertraline. However, possible gender 
effects should be taken into account.
Keywords: oxybutynin, sweating, sertraline, major depressive disorders
Introduction
Depression is a recurrent illness requiring use of antidepressants over prolonged 
periods of time to treat acute and severe episodes and to prevent further episodes of 
depression.1 Over the last 50 years, a variety of antidepressants has been developed,2 
and, of these, selective serotonin reuptake inhibitors (SSRIs) have been widely used 
because of their limited side effects.3–6 However, unwanted drug effects are often 
a factor limiting compliance, so tolerability should be carefully considered at the 
beginning of treatment. Frequent side effects of SSRIs include: headaches, dizziness, 
sexual dysfunction, bleeding, anorexia, nausea, palpitations, chest pain, muscle pain, 
and sweating. Sweating, in particular, is one of the commonly reported and most 
unpleasant side effects. Excessive sweating, termed hyperhidrosis, is a condition 
caused by hyperactivity of the sweat glands. This hyperactivity may be local or 
generalized. According to Stahl,7 10% of patients using SSRIs reported sweating as 
an unpleasant side effect, with even higher prevalence rates in patients using sertraline 
(18.75%) compared with other SSRIs (13.4%). Data from an observational Dutch 
study including 659 patients experiencing a major depressive disorder and using 
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sertraline and 592 patients experiencing a major depressive 
disorder using other SSRIs showed that those using sertraline 
reported sweating more frequently as an adverse effect than 
those using other SSRIs.8 Moreover, increased sweating may 
negatively affect patients’ quality of life, interfere with daily 
activities and social and occupational functioning, and result 
in noncompliance with treatment.9,10 Moreover, tolerance 
normally does not develop, even after a prolonged period 
of treatment.11
To explain excessive sweating with SSRIs, it is 
claimed that SSRIs do reduce norepinephrine reuptake, 
which in turn stimulates peripheral receptors.12 However, 
given the differences in chemical structure and specific 
5-hydroxytryptamine reuptake inhibition characteristics 
between the individual SSRIs, these agents also differ in their 
side effect profiles.3–7 In this regard, it has been suggested 
that sertraline may increase peripheral receptor stimulation.12 
To reduce excessive sweat gland activity, parasympatholytic 
agents might be indicated. Oxybutynin acts as an antagonist 
of muscarinic M-acetylcholine receptors, and a few studies 
have demonstrated the eff icacy of oxybutynin in the 
treatment of hyperhidrosis in otherwise healthy subjects.13,14 
Currently, there is very little published research on the 
treatment of SSRI-induced hyperhidrosis in patients with 
depression.15,16 Therefore, the aim of the present randomized, 
double-blind, placebo-controlled trial was to investigate the 
effect of oxybutynin on sweating in patients suffering from 
major depressive disorder and taking sertraline. Like other 
investigators,13–17 we expected a decreased rate of subjective 
sweating in patients experiencing a major depressive disorder 
with oxybutynin (treatment group) as compared with those 
experiencing a major depressive disorder with placebo 
(control group).
Methods and materials
Sample
A total of 140 patients (mean age 37.69 ± 10.44 years, 
including 86 females [61.4%]) experiencing a major 
depressive disorder were consecutively recruited into this 
double-blind, placebo-controlled randomized clinical trial. 
Of the 145 patients approached, 140 (96.6%) took part, 
whereas five (3.4%) were excluded due to adverse effects 
as described below. Excluded patients did not differ from 
participants with regard to demographic data or degree of 
sweating. Sample characteristics are reported in Table 1. 
Patients in the treatment (oxybutynin) group did not differ 
from the control group (placebo) in demographics, sertraline 
dose, or presenting sweating sites. Inclusion criteria were: 
major depressive disorder as rated by experts according to 
the Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition, Text Revision;18 treatment with sertraline 
in average doses of 50–100 mg/day for at least 14 days; 
excessive sweating related to sertraline; physically healthy, 
ie, no other medical disorder, eg, hypertension, diabetes, or 
endocrine disorders, such as thyroid disease; and completion 
of a consent form to participate in the study. Exclusion 
criteria were psychiatric morbidity; substance abuse; 
intolerable or dangerous side effects due to consumption of 
oxybutynin or placebo, such as gastrointestinal discomfort 
and urinary retention, dry mouth, and double vision (three 
in the treatment group and two in the placebo group were 
excluded due to these side effects); refusal to provide written 
Table 1 Demographic data, sertraline dose, and presenting site of sweating for oxybutynin and placebo groups
Oxybutynin group  
(n = 66)
Placebo group  
(n = 74)
Statistics
Age (years, mean ± SD) 37.12 ± 11.47 38.27 ± 9.47 t(138) = 0.65, P = 0.52
Height (cm, mean ± SD) 166.98 ± 10.48 165.40 ± 9.71 t(138) = 0.86, P = 0.39
Weight (kg, mean ± SD) 71.39 ± 14.07 69.60 ± 14.57 t(138) = 0.80, P = 0.43
Body mass index (mean ± SD) 25.70 ± 4.61 25.63 ± 6.09 t(138) = 0.06, P = 0.96
Gender (male/female; number;  
% within same gender)
27 (50%); 39 (45.3%) 27 (50%); 47 (54.7%) χ2 (df = 1; n = 140) = 0.29, P = 0.59
Sertraline dose (mg/day, mean ± SD) 89.01 ± 49.05 77.70 ± 38.50 t(138) = 1.53, P = 0.13
Duration of sertraline use (days) 19.66 ± 26.84 18.75 ± 25.36 t(138) = 0.21, P = 0.84
Presenting site of sweating
 Whole body 37 (60.7%) 24 (39.3%) χ2 (df = 4, n = 140) = 8.34, P = 0.08
 Head and neck 12 (33.3%) 24 (66.7%)
 Axilla 8 (40%) 12 (60%)
 Palms 2 (33.3%) 4 (66.7%)
Abbreviation: SD, standard deviation.
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informed consent; pregnancy; and breast-feeding. The study 
was performed at the Behavioral Disorders and Substance 
Abuse Research Center in Farshchian Hospital, Hamadan, 
Iran. All participants were outpatients and provided their 
written informed consent. The study was approved by the 
local ethics committee and performed in accordance with the 
ethical standards laid down in the Declaration of Helsinki.
Procedure
Using a quasi-randomized approach, the subjects were assigned 
either to a treatment group (oxybutynin) or to a control group 
(placebo). Neither patients nor the study nurses or physicians 
were informed of group assignment. Sampling occurred as 
follows: 75 red and 75 black chips were put in a ballot box; 
patients drawing a red chip were assigned to the target group 
and patients drawing a black chip were assigned to the control 
group. Sampling continued until a sample of 140 was reached; 
at this point, there were 66 patients in the active treatment group 
(47%) and 74 patients in the control group (53%).
Oxybutynin 5 mg/day or placebo were given as tablets 
of identical shape and color, and the packaging of both 
compounds was likewise identical. The study continued 
for 2 consecutive weeks. At the beginning of the study, 
participants completed a questionnaire related to demographic 
data and presenting site of sweating; at the beginning and 
end of the study, participants also completed a questionnaire 
related to degree of sweating, whereas adverse effects were 
assessed at the end of the study.
Subjective sweating
To assess subjective sweating, patients completed the 
Hyperhidrosis Disease Severity Scale (HDSS),19 consisting 
of four levels of sweating, and participants ticked the box 
reflecting the respective grade of sweating: grade 1, sweating 
is never noticeable and causes no trouble in daily activities; 
grade 2, sweating is tolerable but sometimes interferes in daily 
activities; grade 3, sweating is barely tolerable and frequently 
interferes in daily activities; and grade 4, sweating is never 
tolerable and permanently interferes in daily activities.
Adverse side effects
To assess side effects, participants completed a self-report 
questionnaire, requiring “yes” or “no” responses and related to 
unwanted side effects such as gastrointestinal complications, 
sedation, dry mouth, and urinary complications.
Statistical analysis
By considering the fact that sweating is reported to occur in 
18.7% of patients treated with sertraline7 and assuming that 
oxybutynin is able to reduce sweating by 9%, we included at 
least 62 patients in each group to achieve a statistical power 
of 0.80 with a type I error of 0.05. Comparisons between the 
treatment and control groups using single t-tests and Chi-squared 
t-tests were made with respect to demographic data (age, height, 
weight, body mass index, gender) and data relating to medica-
tion (dose and duration of sertraline intake) and sweating areas 
(whole body, head and neck, axilla, palms). Differences in 
sweating levels and adverse effects were calculated using Chi-
square tests. To explore possible interactions between gender, 
time, and treatment, a series of multivariate analyses of variance 
were performed with the factors of time (measurements before 
and after treatment), treatment (oxybutynin versus placebo), and 
gender (female versus male), and mean scores on the HDSS as 
the dependent variable. The nominal level of significance was 
set at alpha # 0.05. All calculations were performed using SPSS 
version 19.0 for Windows (SPSS Inc, Chicago, IL). 
Table 2 Descriptive and inferential statistics of sweating severity before and after two weeks of administration of oxybutynin or placebo
Oxybutynin (n = 66) Placebo (n = 74) Between-group statistics
Pre Post Comparison 
within group
Pre Post Comparison 
within group
Pre;  
comparison 
between groups
Post;  
comparison  
between groups
Statistics X2 (df = 6,  
N = 66) = 18.71,  
P = 0.005
X2 (df = 6,  
N = 74) = 50.23,  
P = 0.000
X2 (df = 2,  
N = 140) = 2.81,  
P = 0.25
X2 (df = 3,  
N = 140) = 9.07,  
P = 0.03
Severity of sweating
Grade 1 0 (0%) 36 (54.5%) 0 (0%) 26 (35.1%)
Grade 2 27 (40.9%) 25 (37.9%) 38 (51.4%) 30 (40.5%)
Grade 3 21 (31.8%) 4 (6.1%) 24 (32.4%) 13 (17.6%)
Grade 4 18 (27.3%) 1 (1.5%) 12 (16.2%) 5 (6.8%)
66 (100%) 66 (100%) 74 (100%) 74 (100%)
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Adverse effects
Table 4 shows the descriptive and inferential statistics 
concerning adverse effects (gastrointestinal complications, 
sedation, dry mouth, urinary complications) in both groups. 
No significantly increased reports of adverse effects were 
observed in the group treated with oxybutynin compared 
with the control group. Descriptively, dry mouth and urinary 
complications were more often reported in the treatment 
group than in the control group (4.4% versus 0%).
Discussion
The key findings of the present double-blind, randomized, 
clinical study of the effects of oxybutynin on sweating in 
patients with major depressive disorder treated with sertraline 
were that, compared with placebo, oxybutynin decreased sub-
jective sweating over time, few adverse effects were reported, 
and female patients reported a greater decrease in sweating 
than male patients, irrespective of treatment allocation.
We expected a decreased rate of subjective sweating in 
patients experiencing a major depressive disorder treated 
with oxybutynin as compared with placebo, and the data we 
obtained fully supported this expectation. Therefore, our 
Table 3 Sweating severity according to time (before versus after treatment), group (oxybutynin versus placebo), and gender (males 
versus females)
Oxybutynin Placebo
Pre Post Pre Post
Male Female Male Female Male Female Male Female 
(n = 27) (n = 39) (n = 27) (n = 39) (n = 27) (n = 47) (n = 27) (n = 47)
M (SD) M (SD) M (SD) M (SD) M (SD) M (SD) M (SD) M (SD)
Mean  
HDSS scores
3.04 (0.90) 2.74 (0.75) 1.78 (0.75) 1.38 (0.59) 3.04 (0.71) 2.43 (0.68) 2.15 (0.82) 1.85 (0.93)
Abbreviations: HDSS, Hyperhidrosis Disease Severity Scale; M, mean; SD, standard deviation.
Results
Sweating at the beginning and end  
of the study
Table 2 provides a descriptive overview of the distribution 
of the severity of sweating as determined by the HDSS 
score at the beginning of the study and 2 weeks later for the 
treatment and control groups. At the beginning of the study, 
the severity of sweating did not differ significantly between 
the treatment and control groups. At the end of the study, 
sweating improved significantly in the treatment compared 
with the control group. Single within-group comparisons 
revealed that the severity of sweating decreased significantly 
in both the treatment and control groups after treatment.
Influence of time, group, and gender  
on subjective sweating
To compare possible time, group, and gender interactions 
further, HDSS means were calculated and used as the 
dependent variable, while time (before versus after treatment), 
group (treatment versus control group) and gender (male 
versus female) were introduced as independent variables 
(Table 3).
Multivariate analyses of variance revealed that mean 
HDSS scores decreased significantly over time (F[1, 136] 
274.11, P = 0.000, η2 = 0.668), and that female patients 
(2.10 ± 0.07) had significantly lower scores (F[1, 136] 
11.18, P = 0.001, η2 = 0.076) compared with male patients 
(2.50 ± 0.09). Contrary to the results above, when introducing 
gender as a further factor, no significant mean differences 
were found between the treatment and control groups 
(F[1, 136] 1.18, P = 0.28, η2 = 0.009). Furthermore, neither 
time by gender nor time by gender by group interactions 
were significant (Fs , 2.80 Ps . 0.10). However, the 
time by group interaction was statistically significant 
(F[1, 136] 21.95, P = 0.000, η2 = 0.139; see Figure 1), with 
greater improvement in the treatment group than in the 
control group.
0
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Time
H
D
S
S
 s
co
re
s
0.5
1
1.5
2
2.5
3
3.5
Figure 1 Hyperhidrosis Disease Severity Scale scores decreased over time, with a 
greater decrease in the oxybutynin group than in the placebo group (significant time 
by group interaction [F(1, 136) 21.95, P = 0.000, η2 = 0.139]).
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results are in line with those reported by previous investiga-
tors,13–16 although the present findings add to the literature in 
an important way in that data were derived from a double-
blind randomized study, which usually does provide unbiased 
and more reliable data. Moreover, given that sweating is often 
observed as an unpleasant side effect of SSRIs, in particular 
sertraline,8 administration of oxybutynin might be consid-
ered to relieve unpleasant sweating and to improve quality 
of life.9,10 In this regard, possible side effects of oxybutynin 
turned out to be descriptively observable (see Table 4), 
although statistically these side effects were no more frequent 
than in the control group. 
Despite these encouraging findings, several considerations 
argue against excessive generalization of the results and favor 
their cautious interpretation. First, although the sample size 
was quite large, the inclusion and exclusion criteria were 
such that findings might not be able to be generalized to 
older patients experiencing a major depressive disorder or 
other comorbid diseases, or to inpatients. Second, we note 
that within the observation time of 2 weeks, sweating was 
also decreased in the control group receiving placebo. This 
observation was unexpected, and the underlying physiological 
and psychological mechanisms remain unclear, although it 
is conceivable that favorable expectations may have been 
responsible for this result. Moreover, it is also conceivable 
that antidepressant treatment per se reduced symptoms 
of depression and anxiety, thereby leading to a general 
downregulation of the psychophysiological system. In 
this respect, sertraline is known to reduce both symptoms 
of depression and anxiety. Third, we note that the amount 
of sweating reported was different between female and 
male patients. Again the underlying physiological and 
psychological mechanisms were not assessed, but we believe 
that future research should take into account a possible gender-
related bias. Fourth, only patients willing and able to follow 
the study protocol were assessed, so a positive selection bias 
cannot be excluded. Fifth, no psychometric data regarding 
severity of depression or changes in depression severity were 
assessed, and investigating the degrees of symptoms might 
have given further insight into the relationship between 
symptom severity, response to pharmacological treatment, 
and sweating. Therefore, future research should assess both 
patient ratings and clinician ratings of depressive symptoms. 
Sixth, factors influencing the degree of sweating such as 
outdoor activities, vocational pursuits, and similar were not 
assessed. Seventh, the degree of sweating was exclusively 
assessed by subjective patient judgments, so future research 
might also introduce objective measurements.20 Lastly, the 
entire pattern of results might have been due to other latent 
as yet unassessed variables. Future research might include 
additional physiological and psychological assessments 
as well as, for instance, a comparison between different 
SSRIs.
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